Lymphoma Clinical Trials

DIFFUSE LARGE B-CELL LYMPHOMA: (4)
1) 2ND line or greater/ SGN35-031: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2) CTMX-M-2029-001 (CytomX) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas.

3) MOR208C310 frontMIND: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate, and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

4)NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.

FOLLICULAR LYMPHOMA Grade 1 to 3a or R/R Marginal Zone Lymphoma (2)
1) INCMOR 0208-301 inMIND: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.

2) NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.

Send UsA Message

    Myra Walks in a Patient’s Shoes

    Myra Walks in a Patient’s Shoes

    In the busy corridors of Charleston Oncology on a triple-booked day of patients, a moment of pure human kindness unfolded, illustrating what it truly means to walk in a patient’s shoes.

    read more
    A Grateful Patient’s Breast Cancer Journey

    A Grateful Patient’s Breast Cancer Journey

    I am currently undergoing treatment for breast cancer at Roper St. Francis Hospital and would like to acknowledge two physicians who truly embody your mission of “healing with compassion, faith and excellence”.

    read more
    National Cancer Survivor Month

    National Cancer Survivor Month

    Please join Charleston Oncology and the American Association for Cancer Research (AACR) in support of National Survivor Month, celebrating those who have fought the disease and those currently in treatment.

    read more
    Call Now Button